Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
54.25
+0.70 (1.31%)
At close: Jun 6, 2025, 4:00 PM
54.49
+0.24 (0.44%)
After-hours: Jun 6, 2025, 7:48 PM EDT
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees
350
Change (1Y)
-23
Growth (1Y)
-6.17%
Revenue / Employee
$3,098,017
Profits / Employee
$1,386,751
Market Cap
6.68B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
HALO News
- 10 days ago - Halozyme to Participate at Upcoming Investor Conferences - PRNewsWire
- 10 days ago - Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - PRNewsWire
- 14 days ago - Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga
- 26 days ago - Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat - Seeking Alpha
- 4 weeks ago - Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS - PRNewsWire
- 4 weeks ago - Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - PRNewsWire
- 5 weeks ago - Halozyme Therapeutics: Still Undervalued Ahead Of Earnings - Seeking Alpha